In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens

Current Pharmaceutical Design

Volumn 17, Issue 27, 2011, Pages 2881-2888

  Srivastava, Shashikant ^a   Gumbo, Tawanda ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Dose optimization; Dosing schedule; Models; Mycobacterium tuberculosis; PK PD

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ANTIBIOTIC AGENT; CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFALAZIL; RIFAMPICIN; RIFAMYCIN; TUBERCULOSTATIC AGENT; XENOBIOTIC AGENT;

AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TOLERANCE; GUINEA PIG; HOLLOW FIBER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPTIMAL DRUG DOSE; PNEUMONIA; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 80053527553     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797470192     Document Type: Article

References (51)

1. WHO. An extended DOTS framework for effective tuberculosis control. Stop TB communicable diseases. WHO/Geneva 2010; WHO/CDS/TB/2003.297.
2. Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol 2011 (doi: 10.1111/j.1365-2125.2011.03940.x).
3. Mayosi BM, Wiysonge CS, Ntsekhe M, et al. Mortality in patients treated for tuberculous pericarditis in sub-Saharan Africa. S Afr Med J 2008; 98: 36-40.
4. Shaw JE, Pasipanodya JG, Gumbo T. Meningeal tuberculosis: high long-term mortality despite standard therapy. Medicine (Baltimore) 2010; 89: 189-95.
5. Pasipanodya JG, McNabb SJ, Hilsenrath P, et al. Pulmonary impairment after tuberculosis and its contribution to TB burden. BMC Public Health 2010; 10: 259.
6. Onyebujoh P, Zumla A, Ribeiro I, et al. Treatment of tuberculosis: present status and future prospects. Bull World Health Organ 2005; 83: 857-65.
7. Gumbo T, Louie A, Liu W, et al. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 2007; 195:194-201.
8. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642-51.
9. Monod J. The growth of bacterial cultures. Ann Rev Microbiol 1949; 3: 371-94.
10. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64: 2062-9.
11. Zhang Y, Permar S, Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 2002; 51: 42-9.
12. Canetti G, Froman S, Grosset J, et al. Mycobacteria: Laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963; 29: 565-78.
13. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 2010; 54: 1484-91.
14. Craig WA. Pharmacodynamics of antimicrobials: General concepts and applications. In: Nightangle CH, Ambrose PG, Drusano G.L, Murakawa T, editors. Antimicrobial pharmacodynamics in theory and practice. New York: Informa Healthcare USA Inc. 2007; p. 1-19.
15. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokineticspharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86.
16. Jeena PM, Bishai WR, Pasipanodya JG, Gumbo T. In silico children and the glass mouse: Clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis. Antimicrob Agents Chemother 2011; 55: 539-45.
17. Gumbo T, Siyambalapitiyage Dona CS, Meek C, Leff R. Pharmacokinetics-Pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: A paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 2009; 53: 3197-204.
18. Drusano GL, Sgambati N, Eichas A, Brown DL, Kulawy R, Louie A. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow fiber infection model. MBio 2010;1 (doi: 10.1128/mBio.00139-1).
19. Ginsburg AS, Woolwine SC, Hooper N, et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 2003; 349: 1977-8.
20. Pasipanodya J, Gumbo T. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother 2011; 55: 24-34.
21. Gumbo T, Louie A, Liu W, et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 2007; 51: 2329-36.
22. Drusano GL, Fregeau C, Liu W, Brown DL, Louie A. Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model. Antimicrob Agents Chemother 2010; 54: 4368-72.
23. Drusano GL, Vanscoy B, Liu W, Fikes S, Brown D, Louie A. Saturability of Granulocyte Kill of Pseudomonas aeruginosa in a Murine Model of Pneumonia. Antimicrob Agents Chemother 2011 (doi:10.1128/AAC.01687-10).
24. Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007; 51: 576-82.
25. Eum SY, Kong JH, Hong MS, et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 2010; 137: 122-8.
26. Deshpande D, Srivastava S, Meek C, Leff R, Gumbo T. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob Agents Chemother 2010; 54: 1728-33.
27. Deshpande D, Srivastava S, Meek C, Leff R, Hall GS, Gumbo T. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. Antimicrob Agents Chemother 2010; 54: 2534-9.
28. Deshpande D, Gumbo T. Pharmacokinetic/pharmacodynamicbased treatment of disseminated Mycobacterium avium. Future Microbiol 2011; 6: 433-9.
29. Deziel MR, Heine H, Louie A, et al. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob Agents Chemother 2005; 49: 5099-106.
30. MacCallum DM, Odds FC. Influence of grapefruit juice on itraconazole plasma levels in mice and guinea pigs. J Antimicrob Chemother 2002; 50: 219-24.
31. Zhang X, Liu H, Weller P, et al. In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor. Pharmacogenomics J 2011; 11: 15-24
32. McCarthy LE, Mannelli P, Niculescu M, Gingrich K, Unterwald EM, Ehrlich ME. The distribution of cocaine in mice differs by age and strain. Neurotoxicol Teratol 2004; 26:839-48.
33. Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob Agents Chemother 2011; 55: 1527-32.
34. Ahmad Z, Klinkenberg LG, Pinn ML, et al. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis 2009; 200: 1136-43.
35. Selkon JB, Devadatta S, Kulkarni KG, et al. The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS. Bulletin of the World Health Organization 1964; 31: 294.
36. Yeager RL, Munroe WG, Dessau FI. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc 1952; 65: 523-46.
37. Dickinson JM, Ellard GA, Mitchison DA. Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis. Tubercle 1968; 49: 351-66.
38. Jayaram R, Shandil RK, Gaonkar S, et al. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004; 48: 2951-7.
39. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokineticspharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47: 2118-24.
40. Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51: 3781-8.
41. Louie A, Liu W, Deziel MR, et al. Pharmacodynamics of rifalazil (Rz) in a mouse thigh model of Staphylococcus aureus (SA) Infection. ICAAC 2004 (Abstract. A-1297).
42. Goutelle S, Bourguignon L, Maire PH, Van GM, Conte JE, Jr., Jelliffe RW. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother 2009; 53: 2974-81.
43. Steenken W, Jr., Wolinsky E. The antituberculous activity of pyrazinamide in vitro and in the guinea pig. Am Rev Tuberc 1954; 70: 367-9.
44. Pasipanodya JG, Gumbo T. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. Antimicrob Agents Chemother 2010; 54: 2847-54.
45. Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis 2010; 201: 1225-31.
46. Gupta P, Jadaun GP, Das R, et al. Simultaneous ethambutol & isoniazid resistance in clinical isolates of Mycobacterium tuberculosis. Indian J Med Res 2006; 123: 125-30.
47. Parsons LM, Salfinger M, Clobridge A, et al. Phenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol. Antimicrob Agents Chemother 2005; 49: 2218-25.
48. Gumbo T, Louie A, Deziel MR, Drusano GL. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob Agents Chemother 2005; 49: 3178-81.
49. Ginsburg AS, Lee J, Woolwine SC, Grosset JH, Hamzeh FM, Bishai WR. Modeling in vivo pharmacokinetics and pharma-codynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system. Antimicrob Agents Chemother 2005; 49: 853-6.
50. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 2010; 54: 3402-7.
51. Ahmad Z, Peloquin CA, Singh RP, et al. PA-824 exhibits timedependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother 2011; 55: 239-45.